Investor Presentaiton

PERFORMANCE AT A GLANCE Financial Performance (1) (million) 1400 1200 1000 800 600 400 200 22,424 22,247 21,557 20,224 20,438 9,688 6,962 9,250 6,444 6,900 7,098 4,608 4,409 3,625 1,700 FY18 FY19 FY20 FY21 FY22 Revenue ■EBITDA PAT NATCO Pharma Stock Performance 0 28-Sep-18 28-Sep-19 FY numbers have been prepared under Ind AS 28-Sep-20 (1) Represents consolidated gross revenue and includes other income (3)As on September 30,, 2023 28-Sep-21 28-Sep-22 28,117 43.2% 41.6% 10,402 7,153 Profitability Margins NATCO 34.1% 32.9% 31.0% 29.0% 37.0% 25.4% 22.8% 20.5% 17.7% 8.3% FY23 FY18 FY19 FY20 FY21 FY22 FY23 ■EBITDA% PAT% Efficiency Ratios Ownership Structure (3) 29% 24% 50.29% 49.71% 23% 18% ■ Promoter ■ Public 15% 14% 12% 11% 5% 4% 18% 15% 28-Sep-23 No. of fully paid-up equity shares held: 17,91,09,870 FY18 FY19 FY20 FY21 FY22 FY23 ■ROE ROCE (2) Represents PAT after minority interest 4

View entire presentation